TYMEinactive

TYME TECHNOLOGIES, INC.

Healthcare·Oncology
Oncology

TYME TECHNOLOGIES, INC. (TYME): 1 pipeline candidate · ~47 mo cash runway. Updated within the last hour.

7.7/10

BioSniper Score

3-factor signal · derived from public data

Cash Runway10.0

46.5 months

Financial Health9.9

D/E 0.08 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for TYME TECHNOLOGIES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$6.4M

Quarterly Burn

$4.8M

Runway

46.5 mo

Revenue

$0

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~May 2030
Today~51 mo out
Catalyst within runway

Pipeline (1 candidate)

DrugPhase
sm-88—

Frequently asked questions

How many drug candidates are in TYME TECHNOLOGIES, INC.'s pipeline?

TYME TECHNOLOGIES, INC. (TYME) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is TYME TECHNOLOGIES, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, TYME TECHNOLOGIES, INC. has approximately 46.5 months of cash runway.

Get the full picture on TYME TECHNOLOGIES, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar